Brostallicin

Phase 2Small molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Brostallicin is one of 93 small molecule programs targeting Myxoid Liposarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myxoid LiposarcomaActive, not recruiting

Breast CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Myxoid LiposarcomaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Soft Tissue SarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Brostallicin

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Phase 2

1 5

Lexiscan

Astellas

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Voltaren

Novartis

Preclinical

1 8

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 9

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 10

Zinecard

CChildren's Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma2 trials

Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00041249·64 enrolled

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00410462·118 enrolled

Multiple Myeloma1 trial

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT00060203·3 enrolled

Myxoid Liposarcoma1 trial

Brostallicin Clinical Trial for Myxoid Liposarcoma

Unknown status·SSystems Medicine LLC·Phase 2·NCT00633165·24 enrolled

Breast Cancer1 trial

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01091454·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Brostallicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brostallicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brostallicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

Brostallicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Soft Tissue Sarcoma2 trials

Multiple Myeloma1 trial

Myxoid Liposarcoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News